Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 129

Similar articles for PubMed (Select 22748591)

1.

Co-formulated elvitegravir, cobicistat, emtricitabine, and tenofovir versus co-formulated efavirenz, emtricitabine, and tenofovir for initial treatment of HIV-1 infection: a randomised, double-blind, phase 3 trial, analysis of results after 48 weeks.

Sax PE, DeJesus E, Mills A, Zolopa A, Cohen C, Wohl D, Gallant JE, Liu HC, Zhong L, Yale K, White K, Kearney BP, Szwarcberg J, Quirk E, Cheng AK; GS-US-236-0102 study team.

Lancet. 2012 Jun 30;379(9835):2439-48. doi: 10.1016/S0140-6736(12)60917-9. Erratum in: Lancet. 2012 Aug 25;380(9843):730.

PMID:
22748591
2.

Single-tablet emtricitabine-rilpivirine-tenofovir as HIV post-exposure prophylaxis in men who have sex with men.

Foster R, McAllister J, Read TR, Pierce AB, Richardson R, McNulty A, Carr A.

Clin Infect Dis. 2015 Jun 29. pii: civ511. [Epub ahead of print]

PMID:
26123937
3.

Comparison of HIV Virologic Failure Rates Between Patients with Variable Adherence to Three Antiretroviral Regimen Types.

Gordon LL, Gharibian D, Chong K, Chun H.

AIDS Patient Care STDS. 2015 Jul;29(7):384-8. doi: 10.1089/apc.2014.0165. Epub 2015 Jun 4.

PMID:
26114665
4.

Analysis of early resistance development at the first failure timepoint in elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate-treated patients.

White K, Kulkarni R, Miller MD.

J Antimicrob Chemother. 2015 Jun 24. pii: dkv149. [Epub ahead of print]

PMID:
26108607
5.

Switching to Co-Formulated Rilpivirine/Emtricitabine/Tenofovir in Virologically Suppressed Patients: Data from a Multicenter Cohort.

Pinnetti C, Di Giambenedetto S, Maggiolo F, Fabbiani M, Sterrantino G, Latini A, Lorenzini P, Ammassari A, Loiacono L, Bellagamba R, Boumis E, Cauda R, Antinori A, Zaccarelli M.

J Acquir Immune Defic Syndr. 2015 Jun 18. [Epub ahead of print] No abstract available.

PMID:
26090757
6.

Vitamin D and Calcium Attenuate Bone Loss With Antiretroviral Therapy Initiation: A Randomized Trial.

Overton ET, Chan ES, Brown TT, Tebas P, McComsey GA, Melbourne KM, Napoli A, Hardin WR, Ribaudo HJ, Yin MT.

Ann Intern Med. 2015 Jun 16;162(12):815-24. doi: 10.7326/M14-1409.

PMID:
26075752
7.

Less Bone Loss With Maraviroc- Versus Tenofovir-Containing Antiretroviral Therapy in the AIDS Clinical Trials Group A5303 Study.

Taiwo BO, Chan ES, Fichtenbaum CJ, Ribaudo H, Tsibris A, Klingman KL, Eron JJ, Berzins B, Robertson K, Landay A, Ofotokun I, Brown T; AIDS Clinical Trials Group A5303 Study Team.

Clin Infect Dis. 2015 Jun 9. pii: civ455. [Epub ahead of print]

PMID:
26060295
9.

Oral and gel tenofovir for genital HSV-2 shedding in immunocompetent women: a double-blind randomized cross-over trial (128/160 chars&spaces).

Bender Ignacio RA, Perti T, Magaret AS, Rajagopal S, Stevens CE, Huang ML, Selke S, Johnston C, Marrazzo J, Wald A.

J Infect Dis. 2015 Jun 4. pii: jiv317. [Epub ahead of print]

PMID:
26044291
10.

Switch to etravirine for HIV-positive patients receiving statin treatment: a prospective study.

Ciaffi L, Cavassini M, Genne D, Delhumeau C, Spycher Elbes R, Hill A, Wandeler G, Fehr J, Stoeckle M, Schmid P, Hirschel B, Montecucco F, Calmy A; Swiss HIV Cohort Study.

Eur J Clin Invest. 2015 Jul;45(7):720-30. doi: 10.1111/eci.12464.

PMID:
25989829
11.

An unexpected interaction between warfarin and cobicistat-boosted elvitegravir.

Good BL, Gomes DC, Fulco PP.

AIDS. 2015 May 15;29(8):985-6. doi: 10.1097/QAD.0000000000000630. No abstract available.

PMID:
25909832
12.

Persistence and adherence to single-tablet regimens in HIV treatment: a cohort study from the French National Healthcare Insurance Database.

Raffi F, Yazdanpanah Y, Fagnani F, Laurendeau C, Lafuma A, Gourmelen J.

J Antimicrob Chemother. 2015 Jul;70(7):2121-8. doi: 10.1093/jac/dkv083. Epub 2015 Apr 22.

PMID:
25904729
13.

Tenofovir alafenamide versus tenofovir disoproxil fumarate, coformulated with elvitegravir, cobicistat, and emtricitabine, for initial treatment of HIV-1 infection: two randomised, double-blind, phase 3, non-inferiority trials.

Sax PE, Wohl D, Yin MT, Post F, DeJesus E, Saag M, Pozniak A, Thompson M, Podzamczer D, Molina JM, Oka S, Koenig E, Trottier B, Andrade-Villanueva J, Crofoot G, Custodio JM, Plummer A, Zhong L, Cao H, Martin H, Callebaut C, Cheng AK, Fordyce MW, McCallister S; GS-US-292-0104/0111 Study Team.

Lancet. 2015 Jun 27;385(9987):2606-15. doi: 10.1016/S0140-6736(15)60616-X. Epub 2015 Apr 15.

PMID:
25890673
14.

Tenofovir alafenamide for HIV infection: is less more?

Wyatt C, Baeten JM.

Lancet. 2015 Jun 27;385(9987):2559-60. doi: 10.1016/S0140-6736(15)60725-5. Epub 2015 Apr 15. No abstract available.

PMID:
25890672
15.

Efficacy and safety of efavirenz 400 mg daily versus 600 mg daily: 96-week data from the randomised, double-blind, placebo-controlled, non-inferiority ENCORE1 study.

ENCORE1 Study Group.

Lancet Infect Dis. 2015 Jul;15(7):793-802. doi: 10.1016/S1473-3099(15)70060-5. Epub 2015 Apr 12.

PMID:
25877963
16.

Differential skeletal impact of tenofovir disoproxil fumarate in young versus old HIV-infected adults.

Grant PM, Kitch D, McComsey GA, Tierney C, Ha B, Brown TT.

HIV Clin Trials. 2015 Mar-Apr;16(2):66-71. doi: 10.1179/1528433614Z.0000000010. Epub 2015 Apr 15.

17.

Tenofovir Alafenamide Versus Tenofovir Disoproxil Fumarate in the First Protease Inhibitor-Based Single-Tablet Regimen for Initial HIV-1 Therapy: A Randomized Phase 2 Study.

Mills A, Crofoot G Jr, McDonald C, Shalit P, Flamm JA, Gathe J Jr, Scribner A, Shamblaw D, Saag M, Cao H, Martin H, Das M, Thomas A, Liu HC, Yan M, Callebaut C, Custodio J, Cheng A, McCallister S.

J Acquir Immune Defic Syndr. 2015 Aug 1;69(4):439-45. doi: 10.1097/QAI.0000000000000618.

PMID:
25867913
18.

Tenofovir-Associated Nephrotoxicity in Children with Perinatally-Acquired HIV Infection: A Single-Centre Cohort Study.

Lim Y, Lyall H, Foster C.

Clin Drug Investig. 2015 May;35(5):327-33. doi: 10.1007/s40261-015-0287-5.

PMID:
25861908
19.

Comparative Safety and Neuropsychiatric Adverse Events Associated With Efavirenz Use in First-Line Antiretroviral Therapy: A Systematic Review and Meta-Analysis of Randomized Trials.

Ford N, Shubber Z, Pozniak A, Vitoria M, Doherty M, Kirby C, Calmy A.

J Acquir Immune Defic Syndr. 2015 Aug 1;69(4):422-9. doi: 10.1097/QAI.0000000000000606.

PMID:
25850607
20.

96-week resistance analyses of the STaR study: rilpivirine/emtricitabine/tenofovir DF versus efavirenz/emtricitabine/tenofovir DF in antiretroviral-naive, HIV-1-infected subjects.

Porter DP, Kulkarni R, Fralich T, Miller MD, White KL.

HIV Clin Trials. 2015 Jan-Feb;16(1):30-8. doi: 10.1179/1528433614Z.0000000009. Epub 2015 Jan 21.

PMID:
25777187
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk